Seattle Genetics, the Bothell, WA-based developer of cancer drugs, said today that it has completed enrollment in the pivotal clinical trial of its lead product candidate, brentuxmab vedotin (SGN-35). The trial recruited 100 patients with relapsed forms of Hodgkin’s disease. The enrollment period was about six months faster than the company expected, so Seattle Genetics expects to have results from the trial sooner as well, by the second half of 2010. The speed of the enrollment helped Seattle Genetics raise $136 million in a stock offering, as we described in this recent feature story.
By posting a comment, you agree to our terms and conditions.